bromodomain and WD repeat domain containing 1 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored BRWD1P1 profile across patient tissues and cancer cell-line models. BRWD1P1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BRWD1P1 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, BRWD1P1 RNA expression shows 11,016 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where BRWD1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRWD1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRWD1P1 survival associations across molecular data types. BRWD1P1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRWD1P1 RNA expression–survival associations across cancer types. High BRWD1P1 expression shows unfavorable associations in KIRC, THCA, READ, PAAD, BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BRWD1P1 RNA expression.
This table summarizes BRWD1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BRWD1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRWD1P1 shows lower tumor expression in KICH. The KICH box plot shows higher BRWD1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p = .039).
This table shows molecular features associated with BRWD1P1 in patient tissues and cancer cell lines. In patient samples, BRWD1P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
